Veracyte

Veracyte is a commercial-stage genomic diagnostics leader with a mission to improve patient care through molecular insights at critical cancer decision points. The company has achieved significant scale, having served over 800,000 patients, and its tests are widely adopted and embedded in major clinical guidelines. Its core strategy revolves around the Veracyte Diagnostics Platform, a proprietary data-generation engine that uses whole-ome profiling and AI to continuously discover new biomarkers, expand test utility, and build robust clinical evidence, fueling both commercial growth and pipeline expansion into areas like minimal residual disease (MRD) detection.

The Veracyte Diagnostics Platform is a proprietary evidence-generation engine that performs whole-ome profiling on every sample, creating a growing multimodal database which is mined with AI and bioinformatics to discover novel biomarkers and fuel the development and validation of new diagnostic tests.

Veracyte competes with specialized genomic test providers (e.g., Myriad, Exact Sciences) in prostate cancer, reference labs in thyroid, and major liquid biopsy players (e.g., Natera, Guardant Health) in MRD. Its competitive moat is built on its unique whole-ome data assets, AI-powered discovery platform, and strong evidence-based inclusion in clinical guidelines.